For several years, our team has been developing a nanoparticle-delivery approach to enable the modulation of NF-κB signaling specifically in M2 polarized TAMs in a translational clinical setting for ovarian cancer via targeted siRNA delivery [23]. This evidence concerns the gene NFKB1 and ovarian cancer.